Nirtek Pty Ltd - IO Private
#

Matthew Hoskin

Director & CEO

DD Checklist

How much total funding has your startup received

~$1.5M including grants.

What percentage do the founders still own?

95%

Did you develop your own technology inhouse?

Yes

What is your Annual Revenue Run Rate?

0

What is your most important metric (name and amount)?

Time to market

Do you own Trademarks or Patents? (please list)

Yes

Patent family 1 (NIRAF method of use patent) granted in Japan, accepted in USA, under assessment in EU. Patent family 2 (device design patent) filed as provisional in Australia.

Nirtek Pty Ltd

$1.5M

Amount Being Raised

Nirtek is developing and commercialising a novel technology to detect unstable coronary plaques. The technology is the result of a collaboration between the Baker Heart & Diabetes Institute & Swinburne University. Initial funding was from an NHMRC grant, and some current funding comes from an MDPP grant as well as the founding institutions themselves. The technology has the potential to save a huge number of lives, since heart attack caused by the rupture of unstable plaques remains the number one cause of death globally. Until now, cardiologists have not been able to determine which plaques are vulnerable to rupture . This device will solve that problem. The device itself is used during a coronary angiogram procedure to quickly and easily determine if a plaque is unstable and vulnerable to rupture, using a patented technology called near infrared autofluorescence (NIRAF). If the plaque is unstable, the cardiologist can treat the plaque there and then by deploying a stent or targeted medication therapy.

Share this: